Abstract:2576 Background: Tumor microenvironment (TME) heterogeneity leads to the discrepancy of survival prognosis and clinical treatment response for HCC patients. Although the documented molecular subtypes moderately describe the TME heterogeneity and characteristics, their clinical application is constrained by several issues. Methods: We integrated three single-cell datasets from 39 HCC patients to describe the TME landscape and identified prognosis-related cell subclusters. Unsupervised clustering of subcluster-specific markers (SSMs) was performed to generate transcriptomic subtypes. The predictive value of these molecular subtypes for prognosis and treatment response was explored in multiple external HCC cohorts and Xiangya real-world HCC cohort with patients who received immune checkpoint blockade (ICB) therapy. Cancer stemness was estimated using bioinformatic methods and in vivo and in vitro experiments. The features of TME were further validated using single-cell RNA-seq and immune repertoire sequencing, mass cytometry (CyTOF) and multiplex immunofluorescence (mIF). Ultimately, we constructed prognosis-related score (PRS)based on machine learning algorithm, and identified the potential therapeutic targets and agents for high-PRS patients. Results: The comprehensive single-cell analysis provided a high-resolution depiction of TME heterogeneity in HCC and confirmed 6 cell subclusters of prognostic relevance. Five transcriptomic subtypes were constructed using SSMs, which possessed different clinical prognosis, stemness characteristics, immune landscape and therapeutic responses. Class 1 indicated an inflamed phenotype with better clinical outcomes, while Class 2 and class 4 demonstrated immune-deserted phenotypes lacking T cells infiltration. Class 5 and class 3 indicated inhibitory tumor immune microenvironment enriched regulatory T cells and suppressive immune checkpoints. Multiple therapeutic cohorts suggested that Class 5 and class 3 were sensitive to ICB and targeted therapy, while Class 1 and Class 2 were more responsive to transcatheter arterial chemoembolization treatment (TACE). Class 4 displayed resistant to all conventional HCC therapies. The PRS performed well in prognostic prediction in multiple HCC cohorts. Four potential therapeutic agents and four targets were further identified for high-PRS HCC patients. Conclusions: Our study generated a clinically valid molecular classification, thereby providing guidance for precision medicine in HCC patients.

Quantitative Proteomic Dissection of a Native 14-3-3ε Interacting Protein Complex Associated with Hepatocellular Carcinoma

Proteomic Dissection of Cell Type-Specific H2AX-interacting Protein Complex Associated with Hepatocellular Carcinoma.

Comprehensive Profiling of Metastasis-Related Proteins in Paired Hepatocellular Carcinoma Cells with Different Metastasis Potentials

Identification of Molecular Subtypes for Integrated Multi-Omics Analysis for Use in Guiding Precision Medicine in Hepatocellular Carcinoma.

Identifying Hepatocellular Carcinoma Driver Genes by Integrative Pathway Crosstalk and Protein Interaction Network

Proteomics of adjacent-to-tumor samples uncovers clinically relevant biological events in hepatocellular carcinoma

In-depth Characterization of the Biomarkers Based on Tumor-Infiltrated Immune Cells Reveals Implications for Diagnosis and Prognosis in Hepatocellular Carcinoma.

Quantitative Proteome Analysis of Hcc Cell Lines with Different Metastatic Potentials by Silac

Laser capture microdissection in comparative proteomic analysis of hepatocellular carcinoma

14-3-3Ε Mediates the Cell Fate Decision-Making Pathways in Response of Hepatocellular Carcinoma to Bleomycin-Induced DNA Damage

A Novel Approach for the Analysis of Single-Cell RNA Sequencing Identifies TMEM14B As a Novel Poor Prognostic Marker in Hepatocellular Carcinoma.

Nano-LC-MS/MS Based Proteomics of Hepatocellular Carcinoma Cells Compared to Chang Liver Cells and Tanshinone IIA Induction.

In Silico Identification of Crucial Genes and Specific Pathways in Hepatocellular Cancer

Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma

Proteomic and Phosphor-Proteomic Signatures of Clinical Hepatitis B Virus-Associated Hepatocellular Carcinoma

Identification and Characterization of Robust Hepatocellular Carcinoma Prognostic Subtypes Based on an Integrative Metabolite‐Protein Interaction Network

Quantitative proteomic profiling of hepatocellular carcinoma at different serum alpha-fetoprotein level

An Analysis Regarding the Association Between Proteasome (PSM) and Hepatocellular Carcinoma (HCC)

Global profiling of proteolytically modified proteins in human metastatic hepatocellular carcinoma cell lines reveals CAPN2 centered network.

Identification of dysfunctional biological pathways and their synergistic mechanism in hepatocellular carcinoma process

Proteomic Fingerprinting of N-linked Glycoproteins Involved in Hepatocellular Carcinoma